亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma

肾透明细胞癌 比例危险模型 列线图 医学 肿瘤科 内科学 危险系数 队列 肾细胞癌 肾切除术 基因签名 阶段(地层学) 癌症 生物标志物 基因表达 基因 生物 肾 置信区间 古生物学 生物化学
作者
Rohit Mehra,Srinivas Nallandhighal,Brittney Cotta,Zayne Knuth,Fengyun Su,Amy Kasputis,Yuping Zhang,Rui Wang,Xuhong Cao,Aaron M. Udager,Saravana M. Dhanasekaran,Marcin Cieślik,Todd M. Morgan,Simpa S. Salami
出处
期刊:JCO precision oncology [Lippincott Williams & Wilkins]
卷期号: (8)
标识
DOI:10.1200/po.23.00565
摘要

PURPOSE Develop and validate gene expression–based biomarker associated with recurrent disease to facilitate risk stratification of clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS We retrospectively identified 110 patients who underwent radical nephrectomy for ccRCC ( discovery cohort). Patients who recurred were matched on the basis of grade/stage to patients without recurrence. Capture whole-transcriptome sequencing was performed on RNA isolated from archival tissue using the Illumina platform. We developed a gene-expression signature to predict recurrence-free survival/disease-free survival (DFS) using a 15-fold lasso and elastic-net regularized linear Cox model. We derived the 31-gene cell cycle progression (mxCCP) score using RNA-seq data for each patient. Kaplan-Meier (KM) curves and multivariable Cox proportional hazard testing were used to validate the independent prognostic impact of the gene-expression signature on DFS, disease-specific survival (DSS), and overall survival (OS) in two validation data sets (combined n = 761). RESULTS After quality control, the discovery cohort comprised 50 patients with recurrence and 41 patients without, with a median follow-up of 26 and 36 months, respectively. We developed a 15-gene (15G) signature, which was independently associated with worse DFS and DSS (DFS: hazard ratio [HR], 11.08 [95% CI, 4.9 to 25.1]; DSS: HR, 9.67 [95% CI, 3.4 to 27.7]) in a multivariable model adjusting for clinicopathologic parameters (including stage, size, grade, and necrosis [SSIGN] score and Memorial Sloan Kettering Cancer Center nomogram) and mxCCP score. The 15G signature was also independently associated with worse DFS and DSS in both validation data sets (Validation A [n = 382], DFS: HR, 2.6 [95% CI, 1.6 to 4.3]; DSS: HR, 3 [95% CI, 1.4 to 6.1] and Validation B (n = 379), DFS: HR, 2.1 [95% CI, 1.2 to 3.6]; OS: HR, 3 [95% CI, 1.6 to 5.7]) adjusting for clinicopathologic variables and mxCCP score. CONCLUSION We developed and validated a novel 15G prognostic signature to improve risk stratification of patients with ccRCC. Pending further validation, this signature has the potential to facilitate optimal treatment allocation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
单纯冰菱完成签到,获得积分10
3秒前
4秒前
minne发布了新的文献求助30
7秒前
嗨害害完成签到,获得积分10
9秒前
10秒前
科研通AI6.4的应助被xiaoping采纳,获得10
10秒前
wangml完成签到,获得积分10
12秒前
迷人宛亦发布了新的文献求助10
15秒前
15秒前
搜集达人的应助被DRJ采纳,获得10
20秒前
zzyyxx完成签到,获得积分10
25秒前
ppp发布了新的文献求助10
28秒前
情怀的应助被迷人宛亦采纳,获得10
29秒前
29秒前
hhh完成签到,获得积分10
30秒前
36秒前
故意的含灵完成签到,获得积分10
41秒前
RiCiLieu完成签到,获得积分20
43秒前
祈愿发布了新的文献求助10
48秒前
51秒前
卓奕雯完成签到 ,获得积分10
56秒前
Maestro_S的应助被科研通管家采纳,获得10
1分钟前
CodeCraft的应助被科研通管家采纳,获得10
1分钟前
深情安青的应助被科研通管家采纳,获得10
1分钟前
Akim的应助被科研通管家采纳,获得10
1分钟前
大模型的应助被沧海云帆采纳,获得10
1分钟前
ppp发布了新的文献求助10
1分钟前
辛勤诗兰完成签到,获得积分10
1分钟前
1分钟前
敏感难摧完成签到,获得积分10
1分钟前
1分钟前
涛1118发布了新的文献求助10
1分钟前
1分钟前
研友_LwlNdn的应助被落叶的怀柔采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
nadia完成签到,获得积分10
1分钟前
沧海云帆发布了新的文献求助10
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165939
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749898
捐赠科研通 7756692
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553385
邀请新用户注册赠送积分活动 2473623